Pharmacokinetic study of rh-IFNα2a in mice and rats after intravenous and intramuscular administration

Abstract

Abstract: AIM: To study pharmacokinetic property of rh-IFNα2a after intravenous (i.v.) and intramuscular (i.m.) injection to mice and rats. METHODS: Double antibody sandwich ELISA analysis was used for testing drug concentration in serum, urine, bile and tissues after i.v.and i.m.administration of rh-IFNα2a in mice and rats.Pharmacokinetic parameters were calculated by DAS software.Immunohistochemistry technique was also adopted to evaluate its distribution characters. RESULTS: Pharmacokinetic model of rh-IFNα2a after i.v.and i.m. was consistent with two-compartment and one-compartment open model respectively, both submitting to first-order kinetic elimination.Rh-IFNα2a was predominantly distributed in kidney and lung tissue.The total drug accumulative excretion quantity in urine was 0.121 %of the administered after rh-IFNα2a 8.19 μg/kg i.v.into mice. The total drug accumulative excretion quantity in bile was 0.247 %of the administered after rh-IFNα2a 4.10 μg/kg i.v.into rats. CONCLUSION: Pharmacokinetic models after i.v.and i.m.rh-IFNα2a are two-compartment open model and one-compartment open model, respectively, both with first-order kinetic elimination.

Key words: interferon, pharmacokinetics, enzymelinked immunosorbent assay

CLC Number:

R969.1

LU Li, CUI Ming-xia, WANG Li, ZHANG Bao-lai, WU Yong-jie. Pharmacokinetic study of rh-IFNα2a in mice and rats after intravenous and intramuscular administration[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(1): 93-97.

References

[1] 中华人民共和国卫生部药政局. 新药临床前研究指导原则[S]. 1999: 57-62.
[2] Wills RJ, Spiegel HE, Soike KF. Pharmacokinetics of recombinant alpha A interferon following i. v. infusion and bolus, i. m. , and p. o. administrations to African green monkeys[J]. J Interferon Res, 1984;4: 399-409.
[3] Bohoslawec O, Trown PW, Wills RJ. Pharmacokinetics and tissue distribution of recombinant human alpha A, D, A D(Bgl), and I interferons and mouse alpha-interferon in mice[J]. J Interferon Res, 1986;6: 207-213.
[4] Ferraiolo BL, Fuller GB, Burnett B, et al. Pharmacokinetics of recombinant human interferon-gamma in the rhesus monkey after intravenous, intramuscular, and subcutaneous administration[J]. J Biol Response Mod, 1988;7: 115-122.
[5] Yamada T, Yamanaka I. Microglial localization of alpha-interferon receptor in human brain tissues[J]. Neurosci Lett, 1995;189: 73-76.
[6] Weihong Pan, William A, Banks, et al. Permeability of the blood-brain and blood-spinal cord barriers to interferons[J]. J Neuroimmunol, 1997;76: 105-111.
[7] Bocci V, Mogensen KE, Muscettola M, et al. Degradation of human 125I-interferon alpha by isolated perfused rabbit kidney and liver[J]. J Lab ClinMed, 1983;101: 857-863.
[8] Bocci V, Pacini A, Muscettola M, et al. The kidney is the main site of interferon catabolism[J]. J Interferon Res, 1982;2: 309-314.
[9] Bocci V, Pacini A, Muscettola M, et al. Renal metabolism of rabbit serum infection[J]. J Gen Virol, 1981;55: 297-304.
[10] Bocci V. Pharmacokinetc studies of interferons[J]. Pharmac Ther, 1981;13: 421-440.
[11] Bocci V, Pessina GP, Pacini A, et al. Pulmonary catabolism of interferons: alveolar absorption of ¹²⁵I-labeled human interferon alpha is accompanied by partial loss of biological activity[J]. Antiviral Res, 1984;4: 211-220.

[1]	WU Yujie, ZHAO Chengcheng, XI Qing. Evaluation of tegacycline regimens in treatment of gram-negative bacterial infections with Monte Carlo simulation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1027-1033.
[2]	XIAO Yue, LI Tangfei, XUE Qianfu. Analysis of the efficacy and safety of Peg-IFN-α in the treatment of essential thrombocythemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1049-1055.
[3]	LI Kun, LI Lulu, LI Nannan, HU Weihong, ZHOU Jianchao. Effects of glycaemic control and CYP3A5 polymorphisms on tacrolimus trough concentrations after adult kidney transplantation [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(7): 767-774.
[4]	HE Xueru, LI Ying, MA Yinling, FU Yuhao, XUN Xuejiao, DONG Zhanjun. Pharmacokinetic interaction study between sorafenib and dapagliflozin in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 498-507.
[5]	HUANG Zhiwei, LI Yi, XU Xiaoyong, ZHANG Lei, SHEN Yifeng, LI Huafang. Comparison of calculation results of five population pharmacokinetic analysis tools [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(5): 525-535.
[6]	LI Mengxue, HE Jie, YU Xiaxia, HU Linlin, SHAO Hua. Research progress in population pharmacokinetics of rituximab [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 468-474.
[7]	YAN Qiangyong, XIANG Daxiong, ZHU Ronghua, YANG Lingfeng, YANG Xiding, LI Jingjing, FAN Xiao, LIU Sai, XIONG Shoujun, FANG Pingfei. Bioequivalence study of cinacalcet hydrochloride tablets in healthy Chinese volunteers [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(2): 171-177.
[8]	LIU Lu, SHI Yufei, HE Qingfeng, XU Fengyan, WANG Kun, CAI Weimin, XIANG Xiaoqiang. Application of population modeling analysis to evaluate the impact of gene polymorphism on drug PK/PD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1275-1282.
[9]	ZHOU Jiating, ZHANG Xuan, XIE Zilan, LI Zhi. Interactions and clinical significance of gut microbiota and levothyroxine [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(11): 1307-1314.
[10]	LI Xuejing, JIANG Jinping, LI Sining, WAN Linfei, ZHOU Xiangxiang, YANG Lian, LAN Ke. A bioequivalence study of generic and brand clozapine in schizophrenic patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1121-1130.
[11]	WU Lili, LIANG Zhi, HUANG Siyong, WANG Yan. Effect of augmented renal clearance (ARC) on the pharmacokinetics, efficacy, and safety of vancomycin in patients with infective endocarditis [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(10): 1139-1145.
[12]	MA Shen, LIU Yushuo, TANG Hui, CHEN Wenbin, GAO Ling. Pharmacokinetics and clinical significance of drugs for improving nonalcoholic fatty liver disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 908-918.
[13]	DAI Jingyi, WANG Jingjing, ZHANG Jing, YU Jicheng, LI Nanyang, HUANG Zhiwei. Clinical application and research progress of inhaled methoxyflurane [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 808-813.
[14]	PAN Shu, WU Yijin, ZHANG Sasa, WANG Qihai, LUO Tingting, YIN Qin. Pharmacokinetics of methotrexate mediated by organic anion transporter 3 in adjuvant induced arthritis rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(5): 516-525.
[15]	WU Juan, WANG Zhiqiang, ZHOU Renpeng, YANG Jingjing, QIN Huiling, ZHANG Qian, LU Chao, HU Wei. Bioequivalence trial of fasting oral sorafenib tosylate tablets in healthy Chinese subjects [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(3): 281-286.